NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today the presentation of two studies highlighting the use of an automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6 in Chicago, Illinois.
The vast majority of men with CRPC have bone metastases and bone scans are the standard imaging modality in these patients. Bone scans indirectly assess tumor activity by measuring bone mineral turnover. The bone scan index quantifies the prostate cancer disease burden shown on a bone scan. Employing artificial intelligence, the aBSI automatically calculates the bone scan index. aBSI permits a faster quantitative assessment of tumor burden compared to manual BSI and is highly reproducible
The first study, entitled, “Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC),” will be featured during an oral presentation on June 3rd. This study is the first evaluation of aBSI in a phase 3 study as a prognostic biomarker for survival in patients with bone-metastatic CRPC. The study demonstrated that in these patients, aBSI at baseline was prognostic for overall and disease specific survival (p <0.0001), progression free survival (p =0.0024), radiographic progression-free survival (rPFS) (p =0.0061), and symptomatic skeletal related events (SSEs) (p =0.0068).
“This large scale study highlights the ability of the aBSI to provide clinically meaningful prognostic information to patients with bone-metastatic CRPC, using a quantitative software method to assess the burden of bone metastases,” said Andrew Armstrong, MD ScM FACP, Associate Professor of Medicine and Surgery, Associate Director for Clinical Research in Genitourinary Oncology Duke Cancer Institute, Duke University, Durham, NC. “This is the largest study to date of this bone scan index and we demonstrate clinically important outcomes associated with increasing BSI including mortality and symptomatic progression, independent of other known factors.”
The second study will be presented at ASCO on June 5th as a poster titled “Translating Prostate Cancer Working Group (PCWG) Criteria into a Quantitative Progression Biomarker in Metastatic Castration Resistant Prostate Cancer (mCRPC)”. This study demonstrates the utility of automated bone scan indexing to quantitatively assess total tumor burden during the course of disease progression as called for by PCWG2 criteria.
“Historically, assessing treatment effects in prostate cancer has been complicated by the dominance of bone metastases relative to soft tissue disease, making it difficult to accurately assess changes in disease burden over time in patients with mCRPC,” said Michael J. Morris, MD of Memorial Sloan Kettering Cancer Center. “There is a significant need for a fully quantitative biomarker to demonstrate treatment response in these patients, and the current data are encouraging that the aBSI reflects clinically relevant changes in bone, and may fulfill this unmet need.”
The schedule for the presentations at ASCO is as follows:
Date & Time: Saturday, June 3, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Oral Abstract Presentation
Title: Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC)
Location: Hall B1
Abstract No.: 5006
Date & Time: Monday, June 5, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Poster Session
Title: Translating Prostate Cancer Working Group (PCWG) criteria into a quantitative progression biomarker in metastatic Castration Resistant Prostate Cancer (mCRPC)
Location: Hall A, Poster Board # 142
Abstract No.: 5068
About Progenics
Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company's pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA ® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL TM ), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
This press release may contain "forward-looking statements" regarding future events. Statements contained in this communication that refer to non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com . Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company's SEC filings.
(PGNX-F)
Contact: Melissa Downs Investor Relations (646) 975-2533 mdowns@progenics.com
